



Erratum

To cite this article: (2010) Erratum, Expert Opinion on Pharmacotherapy, 11:8, 1443-1443, DOI: [10.1517/14656566.2010.487686](https://doi.org/10.1517/14656566.2010.487686)

To link to this article: <https://doi.org/10.1517/14656566.2010.487686>



Published online: 06 May 2010.



Submit your article to this journal [↗](#)



Article views: 219



View related articles [↗](#)

In the Drug Evaluation 'Use of duloxetine in patients with an anxiety disorder, or with comorbid anxiety and major depressive disorder: A review of the literature' by Mancini M *et al.* published in Expert Opinion on Pharmacotherapy (*Expert Opin. Pharmacother.* (2010) **11**(7):1167-1181), the second to last paragraph in the section on Clinical studies and indications for use (Section 4) should have read as follows:

Based on the results of four large, placebo-controlled trials of duloxetine on patients with GAD, the FDA approved the use of duloxetine for the treatment of GAD in February 2007 [25]. The approval by the EMEA for this indication followed in June 2008 at doses of 30 – 120 mg/day [27].

The authors and publishers apologise for any inconvenience caused.

